AQST is trading 11.62% down at $4.41 as the stock faces a renewed selloff tied to FDA-identified deficiencies in its Anaphylm NDA and ongoing securities-fraud litigation.
- The FDA deficiencies have reportedly blocked labeling discussions for the Anaphylm NDA, creating a significant regulatory hurdle that continues to weigh on the share price.
- Negative sentiment is being further reinforced by class-action lawsuit headlines and recent analyst price-target cuts.
- Today's downward move appears to be an extension of these existing legal and regulatory overhangs, as no fresh company-specific catalysts were reported for June 25.